A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP


Abu Dhabi responds to missile debris incident
UAE responds to missile and drone threats
Dubai issues safety guidelines for unsettled weather
UAE and Serbian Presidents discuss bilateral ties, regional developments
UAE reviews security readiness and response to current challenges
UAE air defences intercept 4 missiles, 25 drones on Sunday
UAE floating hospital in Al Arish celebrates Eid with Gaza patients
UAE enjoys robust food security system, says Economy Minister
Abu Dhabi launches initiative to promote community unity
UAE offers condolences over Qatar helicopter crash
Dubai Police launches campaign to fight online fraud
RTA to implement 'Dubai Walk' project in historic Al Ras area
Over 3.2 million visit Sheikh Zayed Grand Mosque Centre during Ramadan, Eid
UAE joins 21 nations in condemning Iranian attacks, closure of Strait of Hormuz
UAE sends condolences to South Korea over factory fire
DoE Chairman reviews efficiency of Abu Dhabi's energy, water ecosystem
Mother's Day: UAE leaders pay special tribute to mothers of fallen heroes
